Keybank National Association OH Makes New $391,000 Investment in Guardant Health, Inc. $GH

Keybank National Association OH purchased a new position in Guardant Health, Inc. (NASDAQ:GH) in the third quarter, HoldingsChannel reports. The firm purchased 6,261 shares of the company’s stock, valued at approximately $391,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Arizona State Retirement System increased its stake in shares of Guardant Health by 1.9% during the third quarter. Arizona State Retirement System now owns 32,967 shares of the company’s stock valued at $2,060,000 after acquiring an additional 606 shares during the period. Knights of Columbus Asset Advisors LLC bought a new position in Guardant Health during the 3rd quarter valued at $1,554,000. TD Waterhouse Canada Inc. increased its position in shares of Guardant Health by 3.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock valued at $306,000 after purchasing an additional 151 shares during the period. Federated Hermes Inc. raised its stake in shares of Guardant Health by 21.2% in the 3rd quarter. Federated Hermes Inc. now owns 1,776,369 shares of the company’s stock worth $110,988,000 after buying an additional 310,931 shares in the last quarter. Finally, Alta Wealth Advisors LLC acquired a new stake in shares of Guardant Health in the third quarter valued at $406,000. 92.60% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Chris Freeman sold 31,452 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $103.07, for a total value of $3,241,757.64. Following the completion of the sale, the insider directly owned 25,987 shares of the company’s stock, valued at $2,678,480.09. This represents a 54.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Terilyn J. Monroe sold 55,167 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the completion of the sale, the insider owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. The trade was a 72.51% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 434,627 shares of company stock worth $45,592,052 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Guardant Health Trading Up 3.5%

Shares of GH stock opened at $101.85 on Friday. The company has a market capitalization of $12.84 billion, a price-to-earnings ratio of -31.73 and a beta of 1.63. Guardant Health, Inc. has a 1-year low of $34.88 and a 1-year high of $120.74. The stock’s fifty day simple moving average is $106.38 and its 200-day simple moving average is $81.68.

Analysts Set New Price Targets

Several equities research analysts have commented on GH shares. Wells Fargo & Company boosted their price target on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Citigroup lifted their price objective on shares of Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. BTIG Research increased their target price on shares of Guardant Health from $100.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, December 12th. UBS Group restated a “buy” rating and issued a $175.00 price target on shares of Guardant Health in a research report on Friday, January 30th. Finally, TD Cowen reissued a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.86.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.